BerGenBio ASA: Invitation to Second Quarter and Half year 2017 Results Presentation and Webcast
Bergen, Norway, 11 August 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the second quarter and half year 2017 on Friday, 18 August 2017. A presentation by BerGenBio’s senior management team will take place at 10.00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A